Anti-JAK1 antibody [EPR24649-58],Abcam,AB324683
Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .
Host
Rabbit
Reactivity
Human, Mouse
Application
WB, Dot
Platform ID
BAB048564707
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data Tyrosine kinase of the non-receptor type, involved in the IFN-alpha/beta/gamma signal pathway (PubMed : 16239216, PubMed : 28111307, PubMed : 32750333, PubMed : 7615558, PubMed : 8232552). Kinase partner for the interleukin (IL)-2 receptor (PubMed : 11909529) as well as interleukin (IL)-10 receptor (PubMed : 12133952). Kinase partner for the type I interferon receptor IFNAR2 (PubMed : 16239216, PubMed : 28111307, PubMed : 32750333, PubMed : 7615558, PubMed : 8232552). In response to interferon-binding to IFNAR1-IFNAR2 heterodimer, phosphorylates and activates its binding partner IFNAR2, creating docking sites for STAT proteins (PubMed : 7759950). Directly phosphorylates STAT proteins but also activates STAT signaling through the transactivation of other JAK kinases associated with signaling receptors (PubMed : 16239216, PubMed : 32750333, PubMed : 8232552). See full target information JAK1
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
- Products>Trial Size Antibodies
Please provide the required information below so that we can quickly source your products.